Najibulrahman Saifulrahman
General Practice · San Leandro, CANPI 1144517756
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 118 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 19.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $632, 5.1 times the $124 reported in 2019. Among general practice clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 118 payments — averaging $16.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$386
- Scilex Pharmaceuticals Inc.$268
- AstraZeneca$231
- AbbVie$221
- Kowa Pharmaceuticals America, Inc.$141
- Lilly USA, LLC$119
- plus $619 from 15 others
What the payments were for
- Food & beverage$1,985100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 25 | $386 |
| Scilex Pharmaceuticals Inc. | 20 | $268 |
| AstraZeneca | 11 | $231 |
| AbbVie(2 entities) | 11 | $221 |
| Kowa Pharmaceuticals America, Inc. | 12 | $141 |
| Lilly USA, LLC | 5 | $119 |
| Boehringer Ingelheim | 6 | $117 |
| GSK | 4 | $95 |
| Astellas Pharma US Inc | 5 | $90 |
| Amgen | 3 | $80 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $42 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $35 |
| Sumitomo Pharma America, Inc. | 2 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $25 |
| Shield Therapeutics Inc | 1 | $20 |
| Cipher Pharmaceuticals US LLC | 1 | $17 |
| Paratek Pharmaceuticals, Inc. | 1 | $16 |
| Johnson & Johnson | 1 | $15 |
| Abbott | 1 | $14 |
| Merck | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
How this compares
$1,985 in reported general payments places this provider in the 90th percentile of 12,963 general practice providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 132 | $154,546 |
| LinzessLinaclotide | 48 | $48,657 |
| OzempicSemaglutide | 46 | $40,750 |
| JanuviaSitagliptin Phosphate | 21 | $29,559 |
| EliquisApixaban | 29 | $27,430 |
| RybelsusSemaglutide | 17 | $22,887 |
| TradjentaLinagliptin | 25 | $20,769 |
| TrintellixVortioxetine Hydrobromide | 15 | $19,126 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 39 | $13,088 |
| BelsomraSuvorexant | 27 | $11,518 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $10,699 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 197 | $8,429 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 193 | $6,216 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 13 | $5,286 |
| Gabapentin | 143 | $3,582 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $117 | $175,315157 claims |
| Novo NordiskOzempic, Rybelsus | $386 | $63,63763 claims |
| AbbVieLinzess | $221 | $48,65748 claims |
| MerckJanuvia, Belsomra | $14 | $41,07748 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $25 | $19,12615 claims |
| GSKTrelegy Ellipta | $95 | $10,69917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 12,963 general practice providers in California.
Other general practice in San Leandro
- Nathan LiLancaster$5.2M
- Milton McCollSan Jose$4.9M
- Frederic MollRedwood City$2.5M
- Bradley ChingUpland$1.4M
- Eric BrassTorrance$755K
- Marc GeissbergerGreenbrae$583K
- Robert CampbellLong Beach$501K
- Varo BoyerNorth Hills$482K
- Michael MiyasakiSacramento$464K
- Apolinar MadrigalCeres$419K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.